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Abstract
Background: Low-abundance mutations in mitochondrial populations (mutations with minor allele frequency≤ 1%),
are associated with cancer, aging, and neurodegenerative disorders. While recent progress in high-throughput
sequencing technology has significantly improved the heteroplasmy identification process, the ability of this
technology to detect low-abundance mutations can be affected by the presence of similar sequences originating from
nuclear DNA (nDNA). To determine to what extent nDNA can cause false positive low-abundance heteroplasmy calls,
we have identified mitochondrial locations of all subsequences that are common or similar (one mismatch allowed)
between nDNA and mitochondrial DNA (mtDNA).
Results: Performed analysis revealed up to a 25-fold variation in the lengths of longest common and longest similar
(one mismatch allowed) subsequences across the mitochondrial genome. The size of the longest subsequences shared
between nDNA and mtDNA in several regions of the mitochondrial genome were found to be as low as 11 bases,
which not only allows using these regions to design new, very specific PCR primers, but also supports the hypothesis
of the non-random introduction of mtDNA into the human nuclear DNA.
Conclusion: Analysis of the mitochondrial locations of the subsequences shared between nDNA and mtDNA
suggested that even very short (36 bases) single-end sequencing reads can be used to identify low-abundance
variation in 20.4% of the mitochondrial genome. For longer (76 and 150 bases) reads, the proportion of the
mitochondrial genome where nDNA presence will not interfere found to be 44.5 and 67.9%, when low-abundance
mutations at 100% of locations can be identified using 417 bases long single reads. This observation suggests that the
analysis of low-abundance variations in mitochondria population can be extended to a variety of large data collections
such as NCBI Sequence Read Archive, European Nucleotide Archive, The Cancer Genome Atlas, and International
Cancer Genome Consortium.
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Background
A mitochondrion has double-stranded circular DNA,
which encodes 37 genes essential for normal cell func-
tions such as cellular energy metabolism, free radical
generation, and apoptosis [1–3]. Due to its high muta-
tion rate and only rudimentary DNA repair capabilities
[4], mtDNA sequences vary among individuals, organs,
and tissues [5, 6]. Furthermore, de-novo mtDNA muta-
tions can accumulate over the lifetime of the individual
and result in progressive deterioration of mitochondrial
function [7–11]. Given that there are 2–10 copies of
mtDNA per mitochondrion and up to 1000 mitochon-
dria per cell [12], mutations in mtDNA are generally
heteroplasmic, with copies of both wild-type and mu-
tant mtDNA in each cell [13]. Low-level heteroplasmy,
mitochondrial DNA mutations with minor allele fre-
quency ≤ 1%, is associated with aging [14], cancer [15],
and neurodegenerative disorders such as Alzheimer’s
[16] and Parkinson’s disease [17].
Most of the techniques traditionally used to detect
heteroplasmy such as Sanger capillary sequencing [18],
high-performance liquid chromatography [19], SNaP-
shot [20], high-resolution melt profiling [21], temporal
temperature gradient gel electrophoresis [22], Invader
assay [23], and surveyor nuclease digestion [24] require
the candidate positions to be pre-defined and do not
allow determination of de-novo heteroplasmic locations.
High Throughput Sequencing (HTS) technology allows
detection of heteroplasmy across multiple locations in
the mitochondrial genome simultaneously, making it
the technology of choice in recent studies [13, 25–27].
However, the ability of this technology to detect het-
eroplasmy, especially low-abundance mutations, has its
limitations. While some studies suggest that false posi-
tive rare variants can be artifacts of the sequencing tech-
nology [28] and mapping algorithms (software) [29–32],
many publications have also focused on the interference
of nuclear sequences of mitochondrial origin (NUMTs)
on the detection of rare variants [33–35]. These studies
generally consider variants with abundance below 2%
potentially false positive and exclude them. The land-
mark work by Li et al. [28] for example, used a large
number of already identified NUMTs to estimate the
accuracy of low-level heteroplasmy calls and distin-
guish them from sequencing errors. This approach,
however, relies on the reference database of NUMTs
used in the analysis.
It is important to emphasize that while using only
NUMTs to identify possible locations in the mitochon-
drial genome where nDNA can cause false positive het-
eroplasmy makes the computational task relatively easy,
the search for NUMTs in human nuclear genomes is not
yet over. Long and highly similar sequences shared be-
tween nuclear and mitochondrial DNA, also called high
fidelity NUMTs are well described [36]. The search for
new NUMTs focused on shorter and less similar subse-
quences continues [37, 38]. The results (potential new
NUMTs) however, vary depending on the sequence simi-
larity threshold, alignment length, and types of search al-
gorithms used in the analysis [38].
To date, the use of paired end sequencing reads is be-
lieved to be the best way to avoid nDNA interference by
making sure that both reads are mapped to the mito-
chondrial genome with appropriate distance between
them. This assumption, however, does not take into con-
sideration that at least 18 known NUMTs are longer that
5000 bases (out of which four are longer than 10,000
bases with the longest known to date is of the size of
14,904 bases) [39]. These NUMTs are able to produce
reads pairs that may mistakenly be attributed as originat-
ing from mtDNA.
An alternative approach to minimize the effects of un-
known (unidentified) NUMTs is including a “nuclear
DNA exclusion” step into the heteroplasmy detection
workflow. The basic idea of this method is to map all se-
quencing reads to the nDNA and completely exclude
them from the analysis [7, 34, 35]. This approach is
computationally expensive: sequencing reads from each
experiment have to be mapped to approximately three
gigabases long human nuclear genome. Additionally, the
outcome of this approach will be significantly affected
by the presence of short (starting from 11 bases) and
very similar regions shared between mtDNA and nDNA
sequences including, but not limited to known NUMTs.
The longest shared (no mismatches) subsequence be-
tween nDNA and mtDNA is 279 bases (starting at pos-
ition 4457 in the mitochondrial genome (NC_012920.1)
and at position 629,627 in chromosome 1). Allowing just
one mismatch, the same region of chromosome 1 extends
to 417 bases (starting from positions 629,489 in chromo-
some 1 and position 4319 in mitochondria). The main dis-
advantage of the “nuclear DNA exclusion” approach is its
exclusion of sequencing reads originating from such re-
gions from consideration. This step artificially reduces
coverage of the corresponding mtDNA regions and may
result in false negative (missing heteroplasmy variants)
outcomes.
To eliminate challenges of both approaches (using
only known NUMTs and nuclear DNA exclusion) we
propose to pre-compute the locations of all subse-
quences in the mitochondrial genome shared perfectly
(no mismatches) and approximately (one mismatch
allowed) between nDNA and mtDNA. This informa-
tion allows to (a) avoid the nuclear DNA exclusion
step so the reads only need to be mapped to the
much smaller mitochondrial genome; (b) exclude am-
biguous (mapped simultaneously to nuclear and mito-
chondrial DNA) reads; and (c) eliminate discrepancies
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due to the incompleteness and subjectivity in the
choice of NUMTs data used in the analysis.
Results and discussion
Interference maps
Exhaustive comparisons of all DNA subsequences present
in the human nuclear and reference mitochondrial ge-
nomes resulted in the creation of two nuclear interference
maps for the mitochondrial genome: the exact match map
and the approximate match map (Fig. 1, and Additional
file 1). The exact match map assigns to each position in
the mitochondrial genome the length of the longest com-
mon subsequence (LCS): the longest subsequence, which
includes given position in the mitochondrial genome and
present simultaneously (without mismatches) in both nu-
clear and mitochondrial genomes. The approximate
match map assigns to each position in the mitochondrial
genome the length of the longest similar subsequence
(LSS): the longest subsequence, which includes given pos-
ition in the mitochondrial genome and present simultan-
eously (with up to one mismatch difference) in both
nuclear and mitochondrial genomes.
As expected, due to the presence of NUMTs and
other regions containing subsequences similar to the
mitochondrial genome, some common/similar subse-
quences between mitochondrial and nuclear DNA appear
to be quite long: longest LCS and LSS among all locations
in the mitochondrial genome are 279 and 417 bases in
length, respectively. Performed calculations (Table 1) re-
vealed the presence of long LCS and LSS in highly studied
genes such as ND2 (NADH dehydrogenase 2), COX1
(cytochrome c oxidase I), MT-COX2 (cytochrome c oxi-
dase II), ATP6 (ATP synthase 6), as well as ATP8 (ATP
synthase protein 8). This observation suggested that in
order to avoid nDNA interference in every location in
these genes, single end reads used in sequencing experi-
ment have to be longer that 417 bases: the maximal length
of LSS. In contrast, longest and average LCS and LSS in
CYTB (cytochrome b), ND3 (NADH dehydrogenase 3),
and ND4L (NADH-ubiquinone oxidoreductase chain 4 L)
genes appeared much shorter, all nDNA interference in
these genes can be avoided by using single end reads as
short as 100 bases. In fact, the frequency distribution of
the LSS across the mitochondrial genome suggests that
for approximately 20.4% using only 36 bases long single
end reads will be enough to avoid the nDNA interference
(44.5 and 67.9% for 76 and 150 bases long reads, respect-
ively). This opens the opportunity to extend analysis of
Fig. 1 The nucleotide-by-nucleotide perfect and approximate match nDNA interference maps for the mitochondrial genome. 8F, 8R, 10F, and
10R are locations of long-range PCR primers used in Li et al. study [27]. “Maximum” (colored in blue) represents the length of the longest identified LCS
(for exact match map) or LSS (for approximate match map) that covers an individual nucleotide position in mtDNA. “Average” (yellow) represents the
average length of the identified LCS or LSS that covers an individual nucleotide position in mtDNA
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low-abundance variation in mitochondrial population to
large data collections such as NCBI Sequence Read Arch-
ive [40], European Nucleotide Archive [41], The Cancer
Genome Atlas [42], and International Cancer Genome
Consortium [43] which were by no means designed to
explore the low-level heteroplasmy in mitochondrial
genome.
Surprisingly, we observed more than a 25-fold differ-
ence in the length of both LCS and LSS across different
locations in the mitochondrial genome. The shortest
Table 1 Longest common and longest similar subsequences in mitochondrial genes












TRNF 71 577 647 93 55.2 127 85.2
RNR1 954 648 1601 219 108.3 228 139.9
TRNV 69 1602 1670 97 95.0 133 128.8
RNR2 1559 1671 3229 99 51.3 155 81.1
TRNL1 75 3230 3304 42 28.6 46 37.3
ND1 956 3307 4262 207 74.0 263 108.6
TRNI 69 4263 4331 207 174.8 417 285.9
TRNQ 72 4400 4329 137 137.0 417 417.0
TRNM 68 4402 4469 279 162.7 417 417.0
ND2 1042 4470 5511 279 131.9 417 242.3
TRNW 68 5512 5579 81 81.0 322 322.0
TRNA 69 5655 5587 240 240.0 322 322.0
TRNN 73 5729 5657 240 240.0 322 322.0
TRNC 66 5826 5761 240 219.8 322 316.3
TRNY 66 5891 5826 182 144.7 380 351.6
COX1 1542 5904 7445 245 145.7 380 255.8
TRNS1 69 7514 7446 204 204.0 333 333.0
TRND 68 7518 7585 204 129.8 333 333.0
COX2 684 7586 8269 188 86.4 333 169.4
TRNK 70 8295 8364 188 188.0 251 251.0
ATP8 207 8366 8572 188 76.2 251 177.3
ATP6 681 8527 9207 141 97.4 224 183.6
COX3 784 9207 9990 126 71.4 207 140.4
TRNG 68 9991 10058 32 29.4 50 45.0
ND3 346 10059 10404 41 24.4 76 36.6
TRNR 65 10405 10469 57 49.4 83 81.6
ND4L 297 10470 10766 57 33.6 84 63.6
ND4 1378 10760 12137 71 37.1 117 70.6
TRNH 69 12138 12206 52 44.9 78 78.0
TRNS2 59 12207 12265 58 50.3 78 62.3
TRNL2 71 12266 12336 58 51.8 61 59.6
ND5 1812 12337 14148 77 34.1 92 53.0
ND6 525 14673 14149 91 52.4 110 78.5
TRNE 69 14742 14674 75 75.0 110 89.0
CYTB 1141 14747 15887 62 27.4 87 43.3
TRNT 66 15888 15953 26 20.0 30 24.0
TRNP 68 15956 16023 32 26.6 40 36.1
Albayrak et al. BMC Genomics  (2016) 17:1017 Page 4 of 10
LCS was only 11 bases long and appeared in two locations
in the ND5 gene. The shortest LSS was 15 bases long and
appeared in two locations of the hypervariable D-loop re-
gion. As one can see in Fig. 1, the locations of the LCS
and LSS do not appear to be random and express a bias to
particular regions of the mitochondrial genome. For ex-
ample, the region located between positions 4000 and
10,000 in the mitochondrial genome contains the vast ma-
jority of long LCS and LSS while the region between posi-
tions 10,000 and 16,000 contains a high concentration of
short LCS and LSS. One possible explanation of these re-
sults can be that the introduction of mitochondrial se-
quences into the nuclear genome has a bias against
certain locations in mtDNA (such as the 10–16 k region).
Another possibility is that some mtDNA sequences have
been introduced into nuclear DNA over earlier periods of
evolution and have accumulated more mutations than
other sequences that have been more recently transferred
from mtDNA to nDNA. The length distributions of LCS
and LSS that almost perfectly fit into a mixture of two and
three Poisson distributions (Fig. 2a-d) also suggested the
involvement of several different mechanisms behind the
origin/evolution of shared mtDNA and nDNA subse-
quences. These observations are also in agreement with
recent work by Tsuji et al. [44] reporting the underrepre-
sentation of D-Loop sequences in nDNA. Performed ana-
lysis, however, pointed to several additional locations in
the mitochondrial genome (including regions within the
RNR1,TRNL1, and ND1 genes) exhibiting properties simi-
lar to D-loop sequences (i.e. being distant from nDNA)
suggesting that these regions could be mutated and/or un-
derrepresented in nDNA (Fig. 1 and Table 1).
Long range PCR primers
The noticeable presence of short subsequences unique to
mtDNA contradicts the common opinion that due to the
NUMTs, primers designed for mtDNA amplification will
always amplify (perhaps linearly) some amount of nDNA.
Although this is true for the primers originally designed
by Meyer et al. for use in long-range amplification [45]
and employed in the Li et al. studies [27, 28, 46] (the loca-
tions of primer pairs for 8 and 10 kb overlapping mtDNA
regions can be found in Fig. 1), performed analysis
suggests that each of these aforementioned primers is
not unique to mtDNA and has many similar se-
quences in nDNA (Table 2, Fig. 3). Furthermore, the
analysis of the frequency distribution of the length of
LCS and LSS revealed that 39 and 72% of locations,
respectively, in the mitochondrial genome are more
specific than the locations chosen for these primers.
In-silico PCR, using MFEprimer-3.0 [47] against the
human genome, shows that these primers can pro-
duce 24 amplicons from the human nuclear genome
(see Additional file 2 for more information).
The best locations for highly specific PCR primers
would be positions where the lengths of the LSS are at
their minima. Several such locations, which are highly
specific for mtDNA, are shown in Fig. 1. As an example,
we tested four of such location and designed new long-
range PCR primers (Table 2, Fig. 3) to amplify this
Fig. 2 Poisson distributions. Approximation of average length of LCS and LSS covering each position in the mitochondrial genome by two (a, c)
and three (b, d) mixed Poisson distributions. The red dashed line represents the joint approximation of the mixed distributions
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region. In-silico PCR using these primers and a human
genome target shows no viable nDNA amplicons (see
Additional file 2 for more information). An in-vivo valid-
ation using Illumina MiSeq at 151 cycles followed by map-
ping to the mitochondrial genome (NC_012920.1) and the
human genome (GRCh38) shows that the proposed
primers allowed a 10% reduction in the proportion of
reads mapped to the nuclear genome at 95% alignment
identity (see Methods section for more details). It is
important to emphasize, however, that proposed primers
are only an example of how the fidelity of long-range PCR
can be improved. Figure 1 shows several (out of many)
possible locations for long-range PCR primers. Testing all
the mitochondria-specific locations could lead to further
improvement of the mtDNA enrichment protocol but it is
beyond the scope of this manuscript.
It is important to emphasize the limitations of the pre-
sented interference maps. The latest human genome
Table 2 Characteristics of four long-range mtDNA PCR primers used by Li et al [27] and four proposed high fidelity long-range
primers








less value of LSS
Percent of positions
in mtDNA with
less value of LSS
Long-range mtDNA
PCR primers used
by Li et al [25]
10 F
(forward_10kb)
CCGTGCAAAGGTAGCATAATC 8 21/84 11,965 72.21%
10R
(reverse_10kb)
TTACTTTTATTTGGAGTTGCACCA 16 24/52 9,125 55.07%
8 F
(forward_8kb)
GGCTTTCTCAACTTTTAAAGGATA 10 24/34 6,504 39.25%
8R
(reverse_8kb)






TACTACCAGACAACCTTAGCCA 0 22/18 218 1.32%
AR
(reverse_10kb)
GAGTCATAAGTGGAGTCCGTAA 0 22/18 217 1.31%
BF
(forward_8kb)
CACCATTTCCGACGGCATCTAC 0 22/16 1 0.01%
BR
(reverse_8kb)
TGCGCCAGGTTTCAATTTCTAT 0 22/18 217 1.31%
Fig. 3 The length distribution of LSS in the mitochondrial genome. 8F, 8R, 10F, and 10R are locations of forward (F) and reverse (R) primers used
for long-range mtDNA amplification by Li et al [27]. AF, AR, BF, and BR are the primers designed to be located in the regions with the lowest similarity
to the nuclear genome
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build (GRCh38) used in the analysis is missing some
sequences from highly repetitious regions, especially
centromeres. Additionally, personal genomic variations
(single nucleotide polymorphisms and structural varia-
tions) and possible variations in NUMTs between indi-
viduals were not included in our computations. More
robust interference maps can be built using a higher
number of mismatches. For these reasons, the presented
interference maps only allow the identification of the
minimum required sequencing read length in mitochon-
drial regions of interest and establishes a confidence
level in the analysis results.
Conclusion
Due to high throughput and rapidly decreasing cost,
HTS offers new opportunities to identify mitochondrial
heteroplasmy including low-level heteroplasmy. The
presence of a significant amount of nDNA, however, can
introduce bias and cause false positive low-level hetero-
plasmy calls. This is especially important for in-solution
capturing techniques, which have become more popular
for mitochondrial heteroplasmy analysis over the last
few years [48–51].
To avoid interference from nDNA at each given loca-
tion, the length of the LSS at that location must be lon-
ger than the length of the sequencing reads. Proposed
maps allow to predict the level of possible nDNA inter-
ference for each location in the mitochondrial genome,
improve the fidelity of rare variant identification, and
guide the choice of the sequencing read length. Per-
formed analysis suggests that heteroplasmy (including
low-level heteroplasmy) can be identified using short
(36, 76, and 150 bases long) single end read for the sig-
nificant part of the mitochondrial genome, which opens
an opportunity to employ the data from a variety of
existing collections such as the Sequence Read Archive
and The Cancer Genome Atlas into the analysis.
Identified locations of short LCS and LSS in the mito-
chondrial genome can also be used to improve the quality
of long-range PCR primers and probes for in-solution
mtDNA capture by eliminating binding to the nuclear
genome. The locations and length distributions of LCS
and LSS support the hypothesis of non-random mtDNA
introduction into human nuclear DNA and suggest that
several regions of the mitochondrial genome (in addition
to the previously reported D-loop) may be underrepre-
sented or mutated after being introduced into nDNA.
Methods
Nuclear, mitochondrial, and NUMTs data
Presented analyses were performed using the human ref-
erence genome (GRCh38). In addition to the sequences
of the 24 chromosomes, this build contains 430 unlocal-
ized scaffolds (genomic subsequences with an identified
chromosome of origin but an unknown location or
orientation) totaling 120,999,704 bases in length. It is
important to emphasize that the widely accepted mito-
chondrial reference genome (NC_012920.1) used in the
presented analysis contains an unknown nucleotide “N”
(position 3106) which was artificially introduced during
the revision of the Cambridge reference sequence of hu-
man mitochondrial DNA [2] to maintain position num-
bering consistent with previous literature [2]. During
mapping and analysis, this nucleotide was removed from
the reference sequence and restored after mapping. The
longest common and longest similar sequence lengths for
this position were assigned to be equal to the corre-
sponding values for the previous (3105) position. The
NUMTs database uploaded by Simone et al. [38] in an
unpublished study, “Revised RHNumtS compilation,”
was downloaded from the NCBI Nucleotide database
[39] in June 2015. The list of accession numbers for the
NUMTs is available in the Additional file 2 document.
HTS data and analysis
In order to find the LCS and LSS between human nu-
clear DNA and mitochondrial DNA, all human reference
sequences were disassembled into overlapping subse-
quences of 450 bases so that each location in the human
genome was associated with two (original and reverse
complement) disassembled subsequences. The initial
choice of the length of sequences used in the analysis
(450 bases) has been made under the assumption that
the maximum length of LSS will be lower than this value
(which appeared to be 417). Otherwise, this value would
be increased and calculations would be repeated. Human-
derived subsequences were de-replicated (duplications ex-
cluded) for future calculations. The nDNA subsequences
were placed in a search efficient data structure (combin-
ation of a sorted array and suffix tree) allowing to perform
an exhaustive search with mismatches (insertions, dele-
tions, and substitutions) for each subsequence and all of
its prefixes. Each prefix of every 450 base-long subse-
quence derived from the mitochondrial genome (includ-
ing complementary sequence) was searched against this
data structure with perfect matching to identify the LCS
and with one permitted mismatch to identify the LSS
starting from each position. Software specifically devel-
oped for this purpose was used in the computations per-
formed on the Lonestar high-performance computing
cluster at the Texas Advanced Computing Center (The
University of Texas at Austin).
The interference maps were created by identifying
each of the longest common and longest similar subse-
quences that included the given position and calculated
the maximum and average length of such subsequences
(Fig. 1, and Additional file 1).
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Poisson fitting
A Gaussian convolution kernel filter (μ = 21 and σ = 3)
was used to reduce the effects of noise in the probability
density functions of average LCS and LSS lengths (Fig. 2).
The statistical models of the distribution were defined as
mixtures of two and three linearly transformed Poisson
distributions where the probability density of LSS and
LCS of the length (l) was defined as:











β1,.., β2 = transformation coefficients of Poisson
distribution;
λ1,.., λ2 = parameters of Poisson distributions;
k = number of Poisson distributions in the mixture.
The fitness function was defined as the sum of squares of
deviations of the model from the observed probability dens-
ity and was optimized using all 3 k − 1 parameters of the
mixture of transformed Poisson distributions (N = num-









F lið Þ−G li; α; β; λ; kð Þð Þ2
The error and parameter values for when the fitness
function reaches its minimum can be found in Table 3.
PCR primer design and validation
Two pairs of primers (pair A and pair B) amplifying
overlapping 10 and 8 kb regions, respectively, of the
mitochondrial genome, were selected from regions
with the lowest similarity to the nuclear genome using
the proposed interference maps. Primer validation was
performed using in-silico PCR using MFEprimer-3.0
[46]. The same software has been used to evaluate the
primers employed by Li et al. [25]. Both specific and
non-specific amplification was predicted for all
primers using the human reference genome (GRCh38)
(see Additional file 2 for more information). An in-vivo
validation of the proposed primers was performed using
human DNA from a de-identified archived specimen.
DNA was isolated using DNeasy Blood and Tissue kit
(Qiagen, CA, USA). The isolated DNA was amplified
using the LongAmp Taq PCR Kit (New England Bio Labs,
MA, USA) under three conditions, varying the annealing
temperature. More details including the PCR amplifica-
tion conditions can be found in the Additional file 2.
Sequencing has been performed using Illumina MiSeq
instrument at 151 cycles. The read filtration step included
trimming reads containing: (a) nucleotides below the qual-
ity threshold of 0.05 (using modified Richard Mott algo-
rithm); (b) two or more unknown nucleotides; and (c)
Nextera tagmentation library adapters. Reads from each
dataset were mapped to the mitochondrial genome
(NC_012920.1) and the human genome (GRCh38, chro-
mosomes only) using the CLC Genomics Workbench
9.0.1 “Map Reads to Contigs” analysis tool. The proposed
primers showed approximately a 10% reduction in
mapping to the human genome at 95% alignment
identity (see Additional file 2 for more information).
Additional files
Additional file 1: Exact and approximate match nuclear DNA
interference maps for the mitochondrial genome. (XLSX 1715 kb)
Additional file 2: Supplementary Materials Document. (DOCX 454 kb)
Table 3 Error and parameter values identified for average length of LCS and LSS distributions using two and three Poisson mixtures
LCS LSS
Mixture of 2 Poisson Distributions
(k = 2)
Mixture of 3 Poisson Distributions
(k = 3)
Mixture of 2 Poisson Distributions
(k = 2)
Mixture of 3 Poisson Distributions
(k = 3)
α1 0.4071 0.1709 0.7556 0.3993
α2 0.5929 0.4195 0.2444 0.2574
α3 0.4097 0.3433
β1 0.5729 0.1030 0.0263 0.0277
β2 0.0472 0.5691 0.5456 0.5980
β3 0.1090 0.1511
λ1 11.3771 14.0520 2.0610 4.2692
λ2 2.5450 11.0717 14.1339 14.5746
λ3 4.96376 7.9806
error 2.8675E-04 3.3724E-05 4.9989E-04 3.6505E-05
Albayrak et al. BMC Genomics  (2016) 17:1017 Page 8 of 10
Abbreviations
HTS: High throughput sequencing; LCS: Longest common subsequence;
LSS: Longest similar subsequence; mtDNA: Mitochondrial DNA;




YF, GG, MR, KK, MP, and LA work was partially supported by the US Defense
Threat Reduction Agency, the Sealy Center for Structural Biology & Molecular
Biophysics and the Institute for Human Infections and Immunity at the
University of Texas Medical Branch and Texas Advanced Computing Center.
SC work was supported in part by the CONACYT (Mexico) project No. 84358.
Availability of data and materials
The sequencing datasets generated during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
YF, WW, LA, IP, and SC designed the experiments and interpreted the results
of all analyses. LA, KK, GG, MR, MP, GA, and AC developed the analysis tools
and analyzed the sequence data. LA, YF, WW, KK, and MP wrote the
manuscript and GG, MR, and IP edited the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The de-identified human sample used in this study has been acquired from
an existing collection.
Author details
1Department of Pharmacology and Toxicology, University of Texas Medical
Branch, 301 University Boulevard, Galveston, TX 77555-0144, USA. 2Sealy
Center for Structural Biology and Molecular Biophysics, University of Texas
Medical Branch, Galveston, TX, USA. 3Department of Computer Science,
University of Houston, Houston, TX, USA. 4Department of Physics, University
of Guadalajara, Guadalajara, Jalisco, Mexico. 5Department of Biology and
Biochemistry, University of Houston, Houston, TX, USA.
Received: 4 January 2016 Accepted: 5 December 2016
References
1. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human
cancer. Curr Mol Med. 2007;7(1):121–31.
2. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell
N. Reanalysis and revision of the Cambridge reference sequence for human
mitochondrial DNA. Nat Genet. 1999;23(2):147.
3. Verma M, Kumar D. Application of mitochondrial genome information in
cancer epidemiology. Clin Chim Acta. 2007;383(1-2):41–50.
4. Bogenhagen DF. Repair of mtDNA in vertebrates. Am J Hum Genet. 1999;
64(5):1276–81.
5. Macmillan C, Lach B, Shoubridge EA. Variable distribution of mutant
mitochondrial DNAs (tRNA(Leu[3243])) in tissues of symptomatic relatives
with MELAS: the role of mitotic segregation. Neurology. 1993;43(8):1586–90.
6. Chinnery PF. Mitochondrial disorders overview. 2014.
7. Goto H, Dickins B, Afgan E, Paul IM, Taylor J, Makova KD, Nekrutenko A.
Dynamics of mitochondrial heteroplasmy in three families investigated via a
repeatable re-sequencing study. Genome Biol. 2011;12(6):R59.
8. Lott MT, Leipzig JN, Derbeneva O, Xie HM, Chalkia D, Sarmady M, Procaccio
V, Wallace DC. mtDNA variation and analysis using MITOMAP and
MITOMASTER. Curr Protoc Bioinformatics. 2013;1(123):1–23. 21-21 23 26.
9. Ramos A, Santos C, Mateiu L, Gonzalez Mdel M, Alvarez L, Azevedo L,
Amorim A, Aluja MP. Frequency and pattern of heteroplasmy in the
complete human mitochondrial genome. PLoS ONE. 2013;8(10):e74636.
10. Wallace DC. Mitochondrial DNA mutations in disease and aging. Environ
Mol Mutagen. 2010;51(5):440–50.
11. Wallace DC. A mitochondrial paradigm of metabolic and degenerative
diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev
Genet. 2005;39:359–407.
12. Robin ED, Wong R. Mitochondrial DNA molecules and virtual number of
mitochondria per cell in mammalian cells. J Cell Physiol. 1988;136(3):507–13.
13. He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu
VE, Diaz Jr LA, Kinzler KW, Vogelstein B, Papadopoulos N. Heteroplasmic
mitochondrial DNA mutations in normal and tumour cells. Nature. 2010;
464(7288):610–4.
14. Smigrodzki RM, Khan SM. Mitochondrial microheteroplasmy and a theory of
aging and age-related disease. Rejuvenation Res. 2005;8(3):172–98.
15. Yu J, Sadakari Y, Shindo K, Suenaga M, Brant A, Almario JA, Borges M,
Barkley T, Fesharakizadeh S, Ford M et al. Digital next-generation
sequencing identifies low-abundance mutations in pancreatic juice samples
collected from the duodenum of patients with pancreatic cancer and
intraductal papillary mucinous neoplasms. Gut. 2016. doi:10.1136/gutjnl-
2015-311166.
16. Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF. High aggregate burden of
somatic mtDNA point mutations in aging and Alzheimer’s disease brain.
Hum Mol Genet. 2002;11(2):133–45.
17. Parker Jr WD, Parks JK. Mitochondrial ND5 mutations in idiopathic
Parkinson’s disease. Biochem Biophys Res Commun. 2005;326(3):667–9.
18. Irwin JA, Saunier JL, Niederstatter H, Strouss KM, Sturk KA, Diegoli TM,
Brandstatter A, Parson W, Parsons TJ. Investigation of heteroplasmy in the
human mitochondrial DNA control region: a synthesis of observations from
more than 5000 global population samples. J Mol Evol. 2009;68(5):516–27.
19. Meierhofer D, Mayr JA, Ebner S, Sperl W, Kofler B. Rapid screening of the
entire mitochondrial DNA for low-level heteroplasmic mutations.
Mitochondrion. 2005;5(4):282–96.
20. Cassandrini D, Calevo MG, Tessa A, Manfredi G, Fattori F, Meschini MC,
Carrozzo R, Tonoli E, Pedemonte M, Minetti C, et al. A new method for
analysis of mitochondrial DNA point mutations and assess levels of
heteroplasmy. Biochem Biophys Res Commun. 2006;342(2):387–93.
21. Dobrowolski SF, Hendrickx AT, van den Bosch BJ, Smeets HJ, Gray J, Miller T,
Sears M. Identifying sequence variants in the human mitochondrial genome
using high-resolution melt (HRM) profiling. Hum Mutat. 2009;30(6):891–8.
22. Wong LJ, Chen TJ, Tan DJ. Detection of mitochondrial DNA mutations using
temporal temperature gradient gel electrophoresis. Electrophoresis. 2004;
25(15):2602–10.
23. Mashima Y, Nagano M, Funayama T, Zhang Q, Egashira T, Kudho J, Shimizu
N, Oguchi Y. Rapid quantification of the heteroplasmy of mutant
mitochondrial DNAs in Leber’s hereditary optic neuropathy using the
Invader technology. Clin Biochem. 2004;37(4):268–76.
24. Bannwarth S, Procaccio V, Paquis-Flucklinger V. Surveyor Nuclease: a new
strategy for a rapid identification of heteroplasmic mitochondrial DNA
mutations in patients with respiratory chain defects. Hum Mutat. 2005;25(6):
575–82.
25. Bai R, Higgs J, Suchy S, Arjona D, Smaoui N, Richard G, Compton J, Bale S,
Parikh S, Tarnopolsky M, et al. Whole mitochondrial genome amplification
and next generation sequencing for the diagnosis of mitochondrial
disorders: yield of 613 cases. Mitochondrion. 2013;13(6):935–6.
26. Huang T. Next generation sequencing to characterize mitochondrial genomic
DNA heteroplasmy. Curr Protoc Hum Genet. 2011;Chapter 19:Unit19.18.
27. Li M, Schonberg A, Schaefer M, Schroeder R, Nasidze I, Stoneking M.
Detecting heteroplasmy from high-throughput sequencing of complete
human mitochondrial DNA genomes. Am J Hum Genet. 2010;87(2):237–49.
28. Li M, Schroeder R, Ko A, Stoneking M. Fidelity of capture-enrichment for
mtDNA genome sequencing: influence of NUMTs. Nucleic Acids Res. 2012;
40(18):e137.
29. Giannoulatou E, Park SH, Humphreys DT, Ho JW. Verification and validation
of bioinformatics software without a gold standard: a case study of BWA
and Bowtie. BMC Bioinform. 2014;15 Suppl 16:S15.
30. Hatem A, Bozdag D, Toland AE, Catalyurek UV. Benchmarking short
sequence mapping tools. BMC Bioinform. 2013;14:184.
31. Li H, Homer N. A survey of sequence alignment algorithms for next-
generation sequencing. Brief Bioinform. 2010;11(5):473–83.
32. Ruffalo M, LaFramboise T, Koyuturk M. Comparative analysis of algorithms
for next-generation sequencing read alignment. Bioinformatics. 2011;27(20):
2790–6.
Albayrak et al. BMC Genomics  (2016) 17:1017 Page 9 of 10
33. Ye F, Samuels DC, Clark T, Guo Y. High-throughput sequencing in
mitochondrial DNA research. Mitochondrion. 2014;17:157–63.
34. Guo Y, Li J, Li CI, Shyr Y, Samuels DC. MitoSeek: extracting mitochondria
information and performing high-throughput mitochondria sequencing
analysis. Bioinformatics. 2013;29(9):1210–1.
35. Samuels DC, Han L, Li J, Quanghu S, Clark TA, Shyr Y, Guo Y. Finding the
lost treasures in exome sequencing data. Trends Genet. 2013;29(10):593–9.
36. Lascaro D, Castellana S, Gasparre G, Romeo G, Saccone C, Attimonelli M.
The RHNumtS compilation: features and bioinformatics approaches to
locate and quantify Human NumtS. BMC Genomics. 2008;9:267.
37. Ramos A, Barbena E, Mateiu L, del Mar GM, Mairal Q, Lima M, Montiel R,
Aluja MP, Santos C. Nuclear insertions of mitochondrial origin: database
updating and usefulness in cancer studies. Mitochondrion. 2011;11(6):946–53.
38. Simone D, Calabrese FM, Lang M, Gasparre G, Attimonelli M. The reference
human nuclear mitochondrial sequences compilation validated and
implemented on the UCSC genome browser. BMC Genomics. 2011;12:517.
39. Calabrese FM, Simone D, Attimonelli M. Primates and mouse NumtS in the
UCSC Genome Browser. BMC Bioinform. 2012;13 Suppl 4:S15.
40. Leinonen R, Sugawara H, Shumway M. The sequence read archive. Nucleic
Acids Res. 2011;39:D19–21.
41. Leinonen R, Akhtar R, Birney E, Bower L, Cerdeno-Tárraga A, Cheng Y,
Cleland I, Faruque N, Goodgame N, Gibson R, et al. The European
nucleotide archive. Nucleic Acids Res. 2011;39:D28–31.
42. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA):
an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:
A68–77.
43. Zhang J, Baran J, Cros A, Guberman JM, Haider S, Hsu J, Liang Y, Rivkin E,
Wang J, Whitty B, et al. International Cancer Genome Consortium Data
Portal—a one-stop shop for cancer genomics data. Database (Oxford). 2011;
2011:bar026.
44. Tsuji J, Frith MC, Tomii K, Horton P. Mammalian NUMT insertion is non-
random. Nucleic Acids Res. 2012;40(18):9073–88.
45. Meyer M, Stenzel U, Myles S, Prufer K, Hofreiter M. Targeted high-
throughput sequencing of tagged nucleic acid samples. Nucleic Acids Res.
2007;35(15):e97.
46. Schonberg A, Theunert C, Li M, Stoneking M, Nasidze I. High-throughput
sequencing of complete human mtDNA genomes from the Caucasus and
West Asia: high diversity and demographic inferences. Eur J Hum Genet.
2011;19(9):988–94.
47. Qu W, Zhang C. Selecting specific PCR primers with MFEprimer. Methods
Mol Biol. 2015;1275:201–13.
48. Fortes GG, Paijmans JL. Analysis of whole mitogenomes from ancient
samples. Methods Mol Biol. 2015;1347:179–95.
49. Lippold S, Xu H, Ko A, Li M, Renaud G, Butthof A, Schroder R, Stoneking M.
Human paternal and maternal demographic histories: insights from high-
resolution Y chromosome and mtDNA sequences. Investig Genet. 2014;5:13.
50. de Sousa F, Bertrand YJ, Nylinder S, Oxelman B, Eriksson JS, Pfeil BE.
Phylogenetic properties of 50 nuclear loci in Medicago (Leguminosae)
generated using multiplexed sequence capture and next-generation
sequencing. PLoS ONE. 2014;9(10):e109704.
51. King TE, Fortes GG, Balaresque P, Thomas MG, Balding D, Maisano Delser P,
Neumann R, Parson W, Knapp M, Walsh S, et al. Identification of the remains
of King Richard III. Nat Commun. 2014;5:5631.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Albayrak et al. BMC Genomics  (2016) 17:1017 Page 10 of 10
